SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verastem, Inc. - VSTM

Group 1 - Pomerantz LLP is investigating claims on behalf of investors of Verastem, Inc. regarding potential securities fraud or unlawful business practices by the company and its officers or directors [1] - Following the news of the investigation, Verastem's stock price dropped by $8.06 per share, representing a decline of 66.17%, closing at $4.12 per share on May 24, 2024 [3] - On May 23, 2024, Verastem announced interim safety and efficacy results from the RAMP 205 Phase 1/2 clinical trial, revealing that 12 patients experienced 19 treatment-emergent serious adverse events [5] Group 2 - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of recovering multimillion-dollar damages for victims of securities fraud and corporate misconduct [4]